To explain the insurmountable/long-lasting binding of biphenyltetrazole-containing AT1-receptor antagonists such as candesartan, to the human angiotensin II type 1-receptor, a model is proposed in which the basic amino acids Lys199 and Arg 167 of the receptor interact respectively with the carboxylate and the tetrazole group of the antagonists. To validate this model, we have investigated the impact of substitution of Lys199 by Ala or Gln and of Arg167 by Ala on the binding properties of [3H]candesartan and on competition binding by candesartan, EXP3174, irbesartan, losartan, angiotensin II (Ang II) and [Sar1-Ile8]angiotensin. Our results indicate that both amino acids play an important role in the AT1-receptor ligand binding. Whereas the negative charge of Lys 199 is involved in an ionic bond with the end-standing carboxylate group of the peptide ligands, its polarity also contributes to the non-peptide antagonist binding. Substitution of Arg167 by Ala completely abolished [3H]Ang II, as well as [3H] candesartan, binding. Whereas these results are in line with the proposed model, it cannot be excluded that both amino acid residues are important for the structural integrity of the AT1-receptor with respect to its ligand binding properties.
Vanderheyden PML, Fierens FLP, De Backer JP,Vauquelin G.Reversible and syntopic interaction between angiotensin II AT1
3.
receptor antagonists, human AT1 receptors expressed in CHOK1 cells. Biochem Pharmacol2000;59:927-35.
4.
Criscione L., de Gasparo M., Bühlmayer P., Whitebread S., Ramjoué HP, Wood J.Pharmacological profile of valsartan: a potent, orally active, non-peptide antagonist of the angiotensin
Fierens FLP, Vanderheyden PML, De Backer J-P.Vauquelin G.
7.
Insurmountable angiotensin II AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol1999;372:199-206.
8.
Vanderheyden P., Fierens FLP, De Backer J-P., Frayman N., Vauquelin G.Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-
9.
K1 cells expressing human angiotensin II AT1 receptors. Brit J Pharmacol1999;126:1057-65.
10.
Fierens FLP, Vanderheyden PML, De Backer J-P.Vauquelin G.Binding of the antagonist [3H]candesartan to angiotensin II
11.
AT1 receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol1999;367:413-22.
12.
Noda M., ShiboutaY., InadaY. et al. Inhibition of rabbit aoric angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol1993;46:311-8.
13.
Cazaubon C., Gougat J., Bousquet F. et al. Pharmacological
14.
characterization of SR 47436, a new non-peptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther1993;265:826-34.
15.
Verheijen I. , Fierens FLP, De Backer JP, Vauquelin G., Vanderheyden PMLInteraction between the partially insurmountable antagonist valsartan, human recombinant angiotensin II type 1 receptors. Fund Clin Pharmacol2001;14:577-85.
16.
Wong PC, Price WA, Chiu AT, Thoolen Mjmc et al. Non-peptide angiotensin II receptor antagonists. IX. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1990;255:211-7.
17.
Timmermans Pbmwm, Wong PC, Chiu AT et al. Angiotensin II receptors, angiotensin II receptor antagonists. Pharmacological Rev1993;45:205-51.
18.
Robertson MJ , Barnes JC, Drew GM et al. Pharmacological profile of GR 117289 in vitro: a novel, potent and specific non
Tamura K., Okuhira M., Mikoshiba I., Hashimoto K.In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist. Biol Pharmacol Bull1997;20:850-5.
21.
Dickinson KE , Cohen RB, Skwish S. et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174 . Br J Pharmacol1994;113:179-89.
22.
Panek RL, Lu GH, Overhisser RW, Major TC, Hodges JC, Taylor DGFunctional studies but not receptor binding can dis
23.
tinguish surmountable from insurmountable AT1 antagonism. J Pharm Exp Ther1995;273:753-61.
24.
De Arriba AF , Gomez-Casajus LA, Cavalcanti F., Almansa C., Garcia-Rafanel J., Forn J.In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR7280 . Eur J Pharmacol1996;318:341-7.
25.
Yu SS, Lefkowitz RJ, Hausdorff WPβ-Adrenergic receptor sequestration: a potential mechanism of receptor resensitisation. J Biol Chem1993 ;268:337-41.
26.
Renzetti A. , Cucci P., Guelfi M., Cirillo R., Salimbeni A., Giachetti A.Pharmacology of LR-B/057, a novel orally active AT1 receptor antagonist. J Cardiovasc Pharmacol1995; 25:354-60.
27.
Fierens FLP , Vanderheyden PML, Gaborik Z. et al. Lys199 Mutation of the human angiotensin II AT1 receptor differentially affects the binding of surmountable, insurmountable nonpeptide antagonists. JRAAS2000;1:283-8.
28.
Cheng YC, Prusoff WHRelationship between the inhibition constant (Ki) and the concentration of inhibitor wich causes 50% inhibition (IC50) of an enzymatic reaction. Mol Pharmacol1973;32:2497-503.
29.
Duncia JV, Chiu AT, Carini DJ et al. The discovery of potent non-peptide angiotensin II receptors antagonists: a new class of potent antihypertensives. J Med Chem1990;33:1312-29.
30.
Inoue Y., Nakamura N., Inagami T.A review of mutagenesis studies on angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism, J Hypertens1997;15:703-14.
31.
Mirua SI, Feng Y.-H, Huasain A., Karnik SSRole of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor.JBiol Chem1999;274:7103-10.
32.
Yamano Y., Ohyama K., Kikyo M. et al. Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem1995;270:14024-30.
33.
Schambye HT , Hjorth SA, Bergsma DJ, Sathe G., Schwartz TWDifferentiation between binding sites for angiotensin II and non-peptide antagonists on the angiotensin II type 1 receptors . Proc Natl Acad Sci USA1994;91:7046-50.
34.
Schambye HT , van Wijk B., Hjorth SA et al. Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists. Br JPharmacol1994;113:331-3.
35.
Noda K., Saad Y., Karnik SSInteraction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J Biol Chem1995; 270:28511-4.
